ClinicalTrials.gg
CompletedNCT05319756Updated Aug 14, 2023Results posted

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

A Phase 4 interventional study of gabapentin 600 mg and gabapentin 1200 mg in Abuse Potential, sponsored by Viatris Specialty LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Viatris Specialty LLC (part of Viatris Inc.) · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2021, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational opioid users.

Read the detailed description

The study includes Screening, a Qualification Phase consisting of a Naloxone Challenge and Drug Discrimination crossover study, a Treatment Phase and Follow-up. Following successful completion of the Qualification Phase the participants will be enrolled in the Treatment phase. The Treatment Phase is a randomized, double-blind, double dummy, placebo- and active controlled, 6 treatment, 10-sequence, 6 period crossover, single-dose, Williams square design study in healthy male and/or female adult, non drug-dependent recreational users. On Day 1 of each of the Treatment Phase 6 periods, which will be separated by a washout of at least 14 days, participants will receive an oral dose of either gabapentin 600 mg or 1200 mg alone, or concomitantly with a 20 mg dose of oxycodone HCl or 20 mg monotherapy of oxycodone HCl or a placebo. Study treatments will be administered under fasted conditions (overnight fast and no food until 4 hours after dosing). Water will be allowed without restriction until 1 hour prior to dosing and 1 hour after dosing.

02

Conditions studied

  • Abuse Potential

Keywords

  • Neurontin
  • Oxycodone
  • Abuse Liability
  • Gabapentin
03

In context

Lead sponsor

Viatris Specialty LLC is the lead sponsor of 5 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of screening. Participants must meet reproductive criteria as outlined in the protocol.
  2. Male and female participants who are overtly healthy. Healthy is defined as no abnormalities identified by a detailed medical history, complete physical examination, vital signs, 12-lead , and/or clinical laboratory tests.
  3. Participants must have drug abuse experience with opioids; ie, must have used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions within the last year and at least once in the 8 weeks before the Screening Visit (Visit 1).
  4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug Discrimination.
  5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  6. (BMI) of 17.5 to 34 kg/m2, inclusive; and a total body weight ≥50 kg (110 lb).
  7. Capable of giving signed as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Current or past diagnosis of any type of drug dependence within the past year. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine) will be assessed by the Investigator using the -IV (DSM-IV) criteria performed at Screening. Current drug use will be allowed if the candidate can produce a negative urine sample and are free of any signs/symptoms of withdrawal. The candidate will be informed if they have a positive breathalyzer test.
  2. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  3. Any condition possibly affecting drug absorption (eg, gastrectomy) excluding cholecystectomy within 1 year prior to study.
  4. Abnormal baseline EtCO2 \<35mm Hg or >45 mm Hg.
  5. Clinical or laboratory evidence of active hepatitis A infection or a history of (HIV) infection, , or , and/or positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb).
  6. Participants with active suicidal ideation or suicidal behavior within 5 years prior to Screening as determined through the use of the Columbia Suicide Severity Rating Scale (C-SSRS) or active ideation identified at Screening or on Day 0.
  7. Participants with any history of sleep apnea, myasthenia gravis or glaucoma.
  8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  9. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.5 for additional details).
  10. Herbal supplements, herbal medications and hormone replacement therapy must be discontinued at least 28 days prior to the first dose of study medication.
  11. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives (whichever is longer) preceding the first dose of investigational product used in this study.
  12. Positive urine drug screen (UDS) for substances of abuse at each admission in Qualification and Treatment Phase, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at his/her discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participate is permitted to participate in any phase of the study.
  13. Unable to abstain from using THC during the Qualification and Treatment Phase of the study.
  14. Has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorders (excluding nicotine and caffeine).
  15. Has a positive alcohol breathalyzer or urine test at each admission to the study center during Qualification and Treatment Phases. Positive results may be repeated and/or participants re scheduled at the Investigator's discretions.
  16. Participants are heavy smokers or users of other types of nicotine products (>20 cigarettes equivalents per day).
  17. Participants are unable to abstain from smoking for at least 2 hours before and at least 8 hours after study drug administration.
  18. Screening sitting blood pressure (BP) >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.
  19. Baseline (screening) 12 lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline (QTc) interval as determined by the Fridericia method (QTcF) >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  20. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • (AST) or alanine aminotransferase (ALT) level >=1.5 × (ULN);
    • Total level >=1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is \<= ULN.
  21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  22. History of sensitivity to heparin or heparin induced thrombocytopenia.
  23. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  24. History of to gabapentin or oxycodone or any of the components in the formulation of the study products.
  25. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Sponsor employees, including their family members, directly involved in the conduct of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    gabapentin 600 mg single dose

    Drug: gabapentin 600 mg

  • Experimental
    gabapentin 1200 mg single dose

    Drug: gabapentin 1200 mg

  • Experimental
    gabapentin 600 mg and oxycodone HCl 20 mg

    Drug: gabapentin 600 mg and oxycodone HCl 20 mg

  • Experimental
    gabapentin 1200 mg and oxycodone HCl 20 mg

    Drug: gabapentin 1200 mg and oxycodone HCl 20 mg

  • Active comparator
    oxycodone HCl 20 mg single dose

    Drug: oxycodone HCl 20 mg

  • Placebo comparator
    placebo single dose

    Drug: placebo

Interventions

  • Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl

  • Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl

  • Druggabapentin 600 mg and oxycodone HCl 20 mg

    Drug page: Gabapentin

    Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg

  • Druggabapentin 1200 mg and oxycodone HCl 20 mg

    Drug page: Gabapentin

    Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg

  • Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin

  • Drugplacebo

    Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl

06

What researchers measure

Primary outcomes

  1. Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).

    Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: up to 48 hours after treatments

Secondary outcomes

  1. Bipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax)

    Time after dosing when the maximum effect for Drug Liking VAS is reached

    Time frame: up to 48 hours after treatments

  2. Bipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)

    Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  3. Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1)

    Area under the effect-time profile from time 0 to 1 hour post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 1 hour post-dose (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, and 1 hour)

  4. Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2)

    Area under the effect-time profile from time 0 to 2 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 2 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, and 2 hours)

  5. Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3)

    Area under the effect-time profile from time 0 to 3 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: up to 3 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, and 3 hours)

  6. Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4)

    Area under the effect-time profile from time 0 to 4 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 4 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours)

  7. Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8)

    Area under the effect-time profile from time 0 to 8 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 8 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours)

  8. Unipolar VAS for "High" - Maximum Effect (Emax)

    Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatments

  9. Unipolar VAS for "High": Time to Maximum Effect (TEmax)

    Time after dosing when the maximum effect for "High" VAS is reached

    Time frame: up to 48 hours after treatments

  10. Area Under the Effect Curve for "High" VAS (AUEClast)

    Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"

    Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  11. Bipolar VAS for "Take Drug Again"

    100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

    Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)

  12. Bipolar VAS for "Overall Drug Liking"

    100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

    Time frame: Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)

  13. Unipolar VAS for "Good Drug Effect"

    100 mm visual analog scale for the question "At this moment, I can feel good drug effects" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatments

  14. Unipolar VAS for "Bad Drug Effect"

    100 mm visual analog scale for the question "At this moment, I can feel bad drug effects" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatments

  15. Unipolar VAS for "Any Drug Effect"

    100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"

    Time frame: up to 48 hours after treatments

  16. Cmax of Gabapentin

    Maximum plasma concentration of gabapentin

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  17. Tmax of Gabapentin

    Time when the maximum concentration of gabapentin is reached

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  18. AUCinf of Gabapentin

    Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of gabapentin

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  19. AUClast of Gabapentin

    Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of gabapentin

    Time frame: Up to 48 hours after treatment (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  20. Half-life (t½) of Gabapentin

    Half-life (t½) of gabapentin

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  21. Cmax of Oxycodone

    Maximum plasma concentration of Oxycodone

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  22. Tmax of Oxycodone

    Time when the maximum concentration of Oxycodone is reached

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  23. AUCinf of Oxycodone

    Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of Oxycodone

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  24. AUClast of Oxycodone

    Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of Oxycodone

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

  25. Half-life (t½) of Oxycodone

    Half-life (t½) of Oxycodone

    Time frame: Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)

07

Results

Posted Aug 14, 2023

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started999999
Completed889988
Not completed110011

Outcome measures

PrimaryBipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).

Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
up to 48 hours after treatments
Reported as:
Mean · Score on a 100 mm scale
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).
Score on a 100 mm scalePlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax).54.89 ± 2.11687.40 ± 3.15657.89 ± 3.14263.62 ± 3.33488.43 ± 3.21692.17 ± 2.713
Statistical analysis
  • Placebo vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 32.8
  • Placebo vs Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.1041 · Mean difference (final values): -5.6
  • Placebo vs Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.3373 · Mean difference (final values): -1.9
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -12.3
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -6.7
  • Placebo vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.0232 · Mean difference (final values): 3.0
  • Placebo vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.2767 · Mean difference (final values): 8.6
SecondaryBipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax)

Time after dosing when the maximum effect for Drug Liking VAS is reached

Time frame:
up to 48 hours after treatments
Reported as:
Median · hours
Bipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax)
hoursPlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking" - Time to Maximum Effect (TEmax)0.25 (0.2 to 24.0)1.00 (0.2 to 3.5)0.25 (0.25 to 2.5)0.28 (0.1 to 12.1)1.00 (0.2 to 12.0)1.50 (0.2 to 4.0)
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)

Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)
units on a scale * hourPlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve From Time 0 to the Last Available Data (AUEClast)2394.21 ± 65.2742661.43 ± 84.2742422.37 ± 85.8552444.4 ± 83.5802744.86 ± 76.3422759.57 ± 74.589
Statistical analysis
  • Placebo Single Dose vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = 0.0016 · Mean difference (final values): 267.1 · 90% CI 128.8 to 405.4
  • Placebo Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.7276 · Mean difference (final values): 29.19 · 90% CI -109 to 167.5
  • Placebo Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.5481 · Mean difference (final values): 50.41 · 90% CI -88.0 to 188.9
  • Placebo Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 350.7 · 90% CI 211.8 to 489.5
  • Placebo Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 364.4 · 90% CI 225.9 to 502.8
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.0050 · Mean difference (final values): -238 · 90% CI -376 to -99.4
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0106 · Mean difference (final values): -217 · 90% CI -356 to -77.8
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.3196 · Mean difference (final values): 83.60 · 90% CI -54.9 to 222.1
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.2464 · Mean difference (final values): 97.29 · 90% CI -41.0 to 235.6
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1)

Area under the effect-time profile from time 0 to 1 hour post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
Up to 1 hour post-dose (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, and 1 hour)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1)
units on a scale * hourPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 1 Hour (AUEC1)50.17 ± 0.31758.86 ± 1.47851.28 ± 1.44050.61 ± 0.56857.02 ± 1.77155.76 ± 1.390
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2)

Area under the effect-time profile from time 0 to 2 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
Up to 2 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, and 2 hours)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2)
units on a scale * hourPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 2 Hours (AUEC2)102.62 ± 1.791140.44 ± 4.434105.20 ± 4.017107.19 ± 2.449138.72 ± 4.340133.84 ± 4.010
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3)

Area under the effect-time profile from time 0 to 3 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
up to 3 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, and 3 hours)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3)
units on a scale * hourPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 3 Hours (AUEC3)155.48 ± 3.651219.31 ± 7.614161.07 ± 6.535164.03 ± 4.819223.22 ± 7.326214.99 ± 6.567
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4)

Area under the effect-time profile from time 0 to 4 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
Up to 4 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4)
units on a scale * hourPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 4 Hours (AUEC4)208.32 ± 5.171294.28 ± 10.329214.53 ± 8.878220.08 ± 6.896305.08 ± 10.423293.99 ± 8.810
SecondaryBipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8)

Area under the effect-time profile from time 0 to 8 hours post-dose for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

Time frame:
Up to 8 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours)
Reported as:
Mean · units on a scale * hour
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8)
units on a scale * hourPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Drug Liking": Area Under the Effect Curve to 8 Hours (AUEC8)411.58 ± 12.224551.53 ± 19.517421.12 ± 17.144438.30 ± 13.862599.96 ± 22.312574.98 ± 18.952
SecondaryUnipolar VAS for "High" - Maximum Effect (Emax)

Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatments
Reported as:
Mean · Score on a 100 mm scale
Unipolar VAS for "High" - Maximum Effect (Emax)
Score on a 100 mm scalePlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Unipolar VAS for "High" - Maximum Effect (Emax)13.45 ± 4.85477.36 ± 5.816028.61 ± 6.55125.21 ± 6.41281.86 ± 5.62088.74 ± 4.210
Statistical analysis
  • Placebo Single Dose vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 64.67 · 90% CI 52.15 to 77.20
  • Placebo Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.0546 · Mean difference (final values): 14.66 · 90% CI 2.13 to 27.1
  • Placebo Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.1286 · Mean difference (final values): 11.58 · 90% CI -0.96 to 24.12
  • Placebo Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 68.99 · 90% CI 56.42 to 81.57
  • Placebo Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 76.37 · 90% CI 63.83 to 88.91
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -50.0 · 90% CI -62.6 to -37.5
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -53.1 · 90% CI -65.7 to -40.5
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.5699 · Mean difference (final values): 4.32 · 90% CI -8.22 to 16.86
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.1243 · Mean difference (final values): 11.70 · 90% CI -0.83 to 24.23
SecondaryUnipolar VAS for "High": Time to Maximum Effect (TEmax)

Time after dosing when the maximum effect for "High" VAS is reached

Time frame:
up to 48 hours after treatments
Reported as:
Median · hours
Unipolar VAS for "High": Time to Maximum Effect (TEmax)
hoursPlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Unipolar VAS for "High": Time to Maximum Effect (TEmax)0.25 (0.2 to 8.0)1.00 (0.3 to 4.0)0.26 (0.2 to 8.0)0.27 (0.1 to 144.9)1.00 (0.2 to 48.1)1.50 (0.2 to 4.1)
SecondaryArea Under the Effect Curve for "High" VAS (AUEClast)

Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 ="extremely"

Time frame:
Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · units on a scale * hour
Area Under the Effect Curve for "High" VAS (AUEClast)
units on a scale * hourPlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Area Under the Effect Curve for "High" VAS (AUEClast)33.45 ± 14.904321.75 ± 46.34686.41 ± 31.541123.74 ± 50.060512.08 ± 66.299425.01 ± 52.651
Statistical analysis
  • Placebo Single Dose vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 286.7 · 90% CI 202.6 to 370.8
  • Placebo Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.2912 · Mean difference (final values): 53.85 · 90% CI -30.2 to 137.9
  • Placebo Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0563 · Mean difference (final values): 97.80 · 90% CI 13.62 to 182.0
  • Placebo Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 484.5 · 90% CI 400.1 to 569.0
  • Placebo Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 396.6 · 90% CI 312.4 to 480.8
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -233 · 90% CI -317 to -149
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -189 · 90% CI -273 to -105
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): 197.8 · 90% CI 113.7 to 282.0
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0320 · Mean difference (final values): 109.9 · 90% CI 25.80 to 194.0
SecondaryBipolar VAS for "Take Drug Again"

100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

Time frame:
Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Reported as:
Least squares mean · Score on a 100 mm scale
Bipolar VAS for "Take Drug Again"
Score on a 100 mm scalePlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Take Drug Again"53.43 ± 2.92872.16 ± 2.91855.19 ± 2.94258.05 ± 2.93579.16 ± 2.94077.85 ± 2.910
Statistical analysis
  • Placebo Single Dose vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 18.73 · 90% CI 14.98 to 22.48
  • Placebo Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.5056 · Mean difference (final values): 1.76 · 90% CI -2.03 to 5.56
  • Placebo Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0760 · Mean difference (final values): 4.62 · 90% CI 0.82 to 8.42
  • Placebo Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 25.73 · 90% CI 21.92 to 29.54
  • Placebo Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 24.42 · 90% CI 20.68 to 28.16
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -17.0 · 90% CI -20.8 to -13.2
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -14.1 · 90% CI -17.9 to -10.3
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0024 · Mean difference (final values): 7.00 · 90% CI 3.22 to 10.79
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0118 · Mean difference (final values): 5.69 · 90% CI 1.98 to 9.41
SecondaryBipolar VAS for "Overall Drug Liking"

100 mm visual analog scale at 24, 36, and 48 hours post-dose for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so". The data from the 24, 36, and 48 hours postdose measurements were combined into a single overall model-adjusted value for 24 to 48 hours post-treatment timeframe by estimation from a mixed model with treatment, period, treatment sequence, time, and treatment\*time as fixed effects, subject nested within sequence as a random effect. The compound symmetric covariance matrix was employed. Data from all time points were included

Time frame:
Up to 48 hours after treatments (Assessments were made at the following timepoints after each treatment for this outcome measure: 24, 36, and 48 hours)
Reported as:
Least squares mean · Score on a 100 mm scale
Bipolar VAS for "Overall Drug Liking"
Score on a 100 mm scalePlacebo Single DoseOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Bipolar VAS for "Overall Drug Liking"51.75 ± 2.89572.06 ± 2.88654.40 ± 2.90958.25 ± 2.90275.90 ± 2.90779.94 ± 2.878
Statistical analysis
  • Placebo Single Dose vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 20.31 · 90% CI 16.61 to 24.01
  • Placebo Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.2439 · Mean difference (final values): 2.65 · 90% CI -1.09 to 6.39
  • Placebo Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0044 · Mean difference (final values): 6.50 · 90% CI 2.75 to 10.25
  • Placebo Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 24.15 · 90% CI 20.39 to 27.91
  • Placebo Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 28.19 · 90% CI 24.50 to 31.88
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -17.7 · 90% CI -21.4 to -13.9
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -13.8 · 90% CI -17.5 to -10.1
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0907 · Mean difference (final values): 3.84 · 90% CI 0.11 to 7.57
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0004 · Mean difference (final values): 7.88 · 90% CI 4.22 to 11.55
SecondaryUnipolar VAS for "Good Drug Effect"

100 mm visual analog scale for the question "At this moment, I can feel good drug effects" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatments
Reported as:
Least squares mean · Score on a 100 mm scale
Unipolar VAS for "Good Drug Effect"
Score on a 100 mm scalePlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Unipolar VAS for "Good Drug Effect"2.54 ± 2.12327.91 ± 2.1176.13 ± 2.1178.73 ± 2.12034.72 ± 2.11932.71 ± 2.113
Statistical analysis
  • Placebo vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 25.37 · 90% CI 22.86 to 27.88
  • Placebo vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.0189 · Mean difference (final values): 3.59 · 90% CI 1.08 to 6.11
  • Placebo vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 6.18 · 90% CI 3.66 to 8.71
  • Placebo vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 32.18 · 90% CI 29.65 to 34.71
  • Placebo vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 30.17 · 90% CI 27.66 to 32.68
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -21.8 · 90% CI -24.3 to -19.3
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -19.2 · 90% CI -21.7 to -16.7
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 6.81 · 90% CI 4.30 to 9.31
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0015 · Mean difference (final values): 4.80 · 90% CI 2.31 to 7.29
SecondaryUnipolar VAS for "Bad Drug Effect"

100 mm visual analog scale for the question "At this moment, I can feel bad drug effects" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatments
Reported as:
Least squares mean · Score on a 100 mm scale
Unipolar VAS for "Bad Drug Effect"
Score on a 100 mm scalePlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Unipolar VAS for "Bad Drug Effect"0.19 ± 1.2114.41 ± 1.2090.82 ± 1.2090.97 ± 1.2104.10 ± 1.2103.41 ± 1.207
Statistical analysis
  • Placebo vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 4.23 · 90% CI 3.01 to 5.45
  • Placebo vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.3933 · Mean difference (final values): 0.63 · 90% CI -0.59 to 1.86
  • Placebo vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.2916 · Mean difference (final values): 0.79 · 90% CI -0.44 to 2.02
  • Placebo vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 3.92 · 90% CI 2.69 to 5.15
  • Placebo vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 3.22 · 90% CI 2.00 to 4.44
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -3.59 · 90% CI -4.81 to -2.38
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -3.44 · 90% CI -4.66 to -2.22
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.6765 · Mean difference (final values): -0.31 · 90% CI -1.53 to 0.91
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.1712 · Mean difference (final values): -1.01 · 90% CI -2.22 to 0.20
SecondaryUnipolar VAS for "Any Drug Effect"

100 mm visual analog scale for the question "At this moment, I can feel any drug effects" where 0 = "not at all" and 100 = "extremely"

Time frame:
up to 48 hours after treatments
Reported as:
Least squares mean · Score on a 100 mm scale
Unipolar VAS for "Any Drug Effect"
Score on a 100 mm scalePlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Unipolar VAS for "Any Drug Effect"3.77 ± 2.16728.46 ± 2.1616.63 ± 2.1627.88 ± 2.16434.34 ± 2.16333.76 ± 2.158
Statistical analysis
  • Placebo vs Oxycodone HCl 20 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 24.70 · 90% CI 22.19 to 27.21
  • Placebo vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = 0.0606 · Mean difference (final values): 2.87 · 90% CI 0.35 to 5.38
  • Placebo vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = 0.0074 · Mean difference (final values): 4.11 · 90% CI 1.59 to 6.64
  • Placebo vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 30.58 · 90% CI 28.05 to 33.10
  • Placebo vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = <.0001 · Mean difference (final values): 29.99 · 90% CI 27.48 to 32.50
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -21.8 · 90% CI -24.3 to -19.3
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg Single Dose · Mixed Models Analysis · p = <.0001 · Mean difference (final values): -20.6 · 90% CI -23.1 to -18.1
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 600 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): 5.88 · 90% CI 3.37 to 8.38
  • Oxycodone HCl 20 mg Single Dose vs Gabapentin 1200 mg and Oxycodone HCl 20 mg · Mixed Models Analysis · p = 0.0005 · Mean difference (final values): 5.29 · 90% CI 2.80 to 7.78
SecondaryCmax of Gabapentin

Maximum plasma concentration of gabapentin

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · micrograms/milliliter
Cmax of Gabapentin
micrograms/milliliterGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Cmax of Gabapentin4.16 ± 1.4226.07 ± 1.9514.17 ± 1.1216.18 ± 1.443
SecondaryTmax of Gabapentin

Time when the maximum concentration of gabapentin is reached

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Median · Hours
Tmax of Gabapentin
HoursGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Tmax of Gabapentin3.13 (1.2 to 6.1)3.13 (1.6 to 6.1)3.13 (1.2 to 8.1)3.13 (1.2 to 8.2)
SecondaryAUCinf of Gabapentin

Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of gabapentin

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · micrograms*hour/milliliter
AUCinf of Gabapentin
micrograms*hour/milliliterGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
AUCinf of Gabapentin41.42 ± 11.79865.38 ± 18.85448.58 ± 12.00975.18 ± 18.431
SecondaryAUClast of Gabapentin

Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of gabapentin

Time frame:
Up to 48 hours after treatment (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · micrograms*hour/milliliter
AUClast of Gabapentin
micrograms*hour/milliliterGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
AUClast of Gabapentin39.76 ± 11.85661.42 ± 19.90047.31 ± 12.14272.73 ± 17.781
SecondaryHalf-life (t½) of Gabapentin

Half-life (t½) of gabapentin

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · Hours
Half-life (t½) of Gabapentin
HoursGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Half-life (t½) of Gabapentin9.14 ± 10.84610.62 ± 7.6748.20 ± 3.5519.19 ± 3.596
SecondaryCmax of Oxycodone

Maximum plasma concentration of Oxycodone

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · nanograms/milliliter
Cmax of Oxycodone
nanograms/milliliterOxycodone HCl 20 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Cmax of Oxycodone44.92 ± 17.33643.82 ± 14.14440.79 ± 14.809
SecondaryTmax of Oxycodone

Time when the maximum concentration of Oxycodone is reached

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Median · hours
Tmax of Oxycodone
hoursOxycodone HCl 20 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Tmax of Oxycodone1.15 (0.6 to 8.1)1.15 (0.6 to 5.9)1.63 (0.6 to 3.6)
SecondaryAUCinf of Oxycodone

Area under the plasma concentration/time curve from time 0 extrapolated to infinity time of Oxycodone

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · nanograms*hour/milliliter
AUCinf of Oxycodone
nanograms*hour/milliliterOxycodone HCl 20 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
AUCinf of Oxycodone233.29 ± 64.369228.40 ± 71.854234.94 ± 77.115
SecondaryAUClast of Oxycodone

Area under the plasma concentration/time profile from time 0 to the time of the last quantifiable concentration of Oxycodone

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Mean · nanograms*hour/milliliter
AUClast of Oxycodone
nanograms*hour/milliliterOxycodone HCl 20 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
AUClast of Oxycodone229.31 ± 64.935224.79 ± 71.748234.65 ± 80.068
SecondaryHalf-life (t½) of Oxycodone

Half-life (t½) of Oxycodone

Time frame:
Up to 48 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, and 48 hours)
Reported as:
Median · hours
Half-life (t½) of Oxycodone
hoursOxycodone HCl 20 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
Half-life (t½) of Oxycodone4.12 (2.6 to 6.2)3.84 (2.2 to 6.1)3.90 (2.4 to 10.7)

Adverse events

Collected over During the entire Treatment Phase of the study, which encompassed the time interval from admission of the subject to their first Treatment Period until 28 days after study drug dosing in their last (6th) Treatment Period, including the washout in between Treatment Periods. The total duration of the Treatment Phase for each subject was dependent on visit scheduling and whether the subject completed all 6 treatment periods, and it lasted up to approximately 13 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/53 (0%)0/53 (0%)0/53 (0%)
Oxycodone HCl 20 mg Single Dose0/52 (0%)0/52 (0%)4/52 (7.7%)
Gabapentin 600 mg Single Dose0/51 (0%)0/51 (0%)0/51 (0%)
Gabapentin 1200 mg Single Dose0/52 (0%)0/52 (0%)2/52 (3.8%)
Gabapentin 600 mg and Oxycodone HCl 20 mg0/52 (0%)0/52 (0%)4/52 (7.7%)
Gabapentin 1200 mg and Oxycodone HCl 20 mg0/52 (0%)0/52 (0%)2/52 (3.8%)
Most frequent other events
Most frequent other events
EventPlaceboOxycodone HCl 20 mg Single DoseGabapentin 600 mg Single DoseGabapentin 1200 mg Single DoseGabapentin 600 mg and Oxycodone HCl 20 mgGabapentin 1200 mg and Oxycodone HCl 20 mg
NauseaGastrointestinal disorders0/534/520/510/524/522/52
VomitingGastrointestinal disorders0/530/520/511/520/520/52
Muscle strainInjury, poisoning and procedural complications0/530/520/511/520/520/52

Baseline characteristics

The randomized population included all participants who were randomized to a treatment sequence in the Treatment Phase.

Age, Continuous
Age, Continuous(Years)Randomized Population
Mean33.3 ± 8.41
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Population
Female16
Male38
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Randomized Population
Hispanic or Latino12
Not Hispanic or Latino42
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomized Population
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American35
White13
More than one race4
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Randomized Population
United States54
08

Study locations

1 site
  • Hassman Research Institute
    Marlton, New Jersey 080503, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Dec 2021, 8 months.

Results were first posted in Aug 2023, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Apr 8, 2022
StartActual
Apr 30, 2021
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05319756
Responsible party
Sponsor
First posted
Apr 8, 2022
Start date
Apr 30, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

Dik WH NG, PhD
study director · Viatris Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion